Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alnuctamab in Refractory Systemic Lupus Erythematosus
NCT07219563Phase 1Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alnuctamab in systemic lupus erythematosus (SLE), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Number of treatment emergent adverse events at 9 days. Started Mar 2026; status: recruiting.
02
Drugs
alnuctamab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07219563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07219563.